Pre-Made Nonacog Gamma Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Nonacog Gamma Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Nonacog gamma is a new recombinant factor IX to treat factor IX deficiency. It is indicated for control of bleeding, perioperative management and routine prophylaxis to prevent or reduce the frequency of bleeding in adults and children with hemophilia B.
| Products Name (INN Index) | Pre-Made Nonacog Gamma Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 |
|---|---|
| INN Name | nonacog gamma |
| Target | F9 |
| Format | Recombinant Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | F9 (coagulation factor 9, coagulation factor IX) recombinant (variant_011773) glycosylated (glycoform alfa) |
| VD LC | F9 (coagulation factor 9, coagulation factor IX) recombinant (variant_011773) glycosylated (glycoform alfa) |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Baxter?BioScience (Westlake Village CA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | F9 |
| Package |
